High density lipoprotein screening: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the [[United states preventive services task force recommendations scheme|United States Preventive Services Task Force (USPSTF)]], screening for dyslipidemia, which includes | According to the [[United states preventive services task force recommendations scheme|United States Preventive Services Task Force (USPSTF)]], screening for dyslipidemia, which includes low HDL-cholesterol (HDL-c), is indicated among men 35 years and older ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: A Recommendation]]), men age 20 to 35 years in case of an elevated risk for [[coronary heart disease]] ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: B Recommendation]]), women age 45 years and older for in case of an elevated risk for [[coronary heart disease]] ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: A Recommendation]]), and women age 20 to 45 years in case of an elevated risk for [[coronary heart disease]] ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: B Recommendation]]).<ref name=USPSTF> Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening] </ref> There is insufficient evidence to recommend for or against screening for [[dyslipidemia]] among infants, children, adolescents, or young adults less than 20 years of age ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: I statement]]).<ref name=USPSTF> Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening] </ref> | ||
==Screening== | ==Screening== | ||
===Screening Indications=== | ===Screening Indications=== | ||
====Screening in Adults==== | ====Screening in Adults==== | ||
Screening for [[dyslipidemia]], including | Screening for [[dyslipidemia]], including low HDL, depends on the gender, age, and the risk for [[coronary heart disease]]. Screening for [[dyslipidemia]] is indicated among the following:<ref name=USPSTF> Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening] </ref> | ||
* Men 35 years and older ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: A Recommendation]]) | * Men 35 years and older ([[United states preventive services task force recommendations scheme#USPSTF Grade Definitions|Grade: A Recommendation]]) | ||
| Line 23: | Line 23: | ||
* Identification of risk factors for [[coronary artery disease]] | * Identification of risk factors for [[coronary artery disease]] | ||
* Estimation of the 10-year risk of [[cardiovascular disease]] | * Estimation of the 10-year risk of [[cardiovascular disease]] | ||
* Measurement of fasting lipid panel (total [[cholesterol]], [[ | * Measurement of fasting lipid panel (total [[cholesterol]], [[HDL]], [[HDL]], [[triglycerides]]) | ||
==References== | ==References== | ||
Revision as of 19:46, 9 October 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein screening On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein screening |
|
Risk calculators and risk factors for High density lipoprotein screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [3]
Overview
According to the United States Preventive Services Task Force (USPSTF), screening for dyslipidemia, which includes low HDL-cholesterol (HDL-c), is indicated among men 35 years and older (Grade: A Recommendation), men age 20 to 35 years in case of an elevated risk for coronary heart disease (Grade: B Recommendation), women age 45 years and older for in case of an elevated risk for coronary heart disease (Grade: A Recommendation), and women age 20 to 45 years in case of an elevated risk for coronary heart disease (Grade: B Recommendation).[1] There is insufficient evidence to recommend for or against screening for dyslipidemia among infants, children, adolescents, or young adults less than 20 years of age (Grade: I statement).[1]
Screening
Screening Indications
Screening in Adults
Screening for dyslipidemia, including low HDL, depends on the gender, age, and the risk for coronary heart disease. Screening for dyslipidemia is indicated among the following:[1]
- Men 35 years and older (Grade: A Recommendation)
- Men 20 to 35 years in case of an elevated risk for coronary heart disease (Grade: B Recommendation)
- Women 45 years and older for in case of an elevated risk for coronary heart disease (Grade: A Recommendation)
- Women 20 to 45 years in case of an elevated risk for coronary heart disease (Grade: B Recommendation)
Screening in Children
There is insufficient evidence to recommend for or against screening for dyslipidemia among infants, children, adolescents, or young adults less than 20 years of age (Grade: I statement).[1]
Screening Components
Screening for dyslipidemia includes:[2]
- Identification of risk factors for coronary artery disease
- Estimation of the 10-year risk of cardiovascular disease
- Measurement of fasting lipid panel (total cholesterol, HDL, HDL, triglycerides)
References
- ↑ 1.0 1.1 1.2 1.3 Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [1]
- ↑ Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW; et al. (2012). "American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary". Endocr Pract. 18 (2): 269–93. PMID 22507559.